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1. INTRODUCTION 
1.1. Prostate cancer 
 Prostate cancer is the second most common malignancy among men in the 
world. Prostate cancer occurs in prostate gland, which is a small walnut-shaped gland 
that produces the seminal fluid that nourishes and transports sperm. Prostate cancer 
usually grows slowly and initially remains confined to the prostate gland, where it may 
not cause serious harm. While some types of prostate cancer grow slowly and may need 
minimal or no treatment, other types are aggressive and can spread quickly. Prostate 
cancer begins when cells in the prostate gland start to grow uncontrollably. 
 The prostate is below the bladder and in front of the rectum. The size of the 
prostate changes with age. In younger men, it is about the size of a walnut, but it can be 
much larger in older men. Just behind the prostate are glands called seminal vesicles 
that make most of the fluid for semen. The urethra, which is the tube that carries urine 
and semen out of the body through the penis, goes through the center of the prostate. 
Prostate cancer occurrence is high in developed countries and recorded the lowest in 
central Asian countries. (Ahmedin et al., 2011) 
 Causative factors for prostate cancer are multiple which include increasing age, 
race, ethnicity, family history, environmental pollution, diet and obesity, smoking, 
frequent sex and sexually transmitted diseases. (Osamu et al., 2002) 
1.2. Types and treatment of prostate cancer 
• Localized prostate cancer 
• Metastatic prostate cancer 
Localized prostate cancer treatment is stage specific. Radical prostatectomy (surgical 
removal of the prostate gland), image guided radiotherapy which includes 3D 
conformal radio therapy and intensity modulated radio therapy are widely used to treat 
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localized prostate cancer. For metastatic prostate cancer the therapy is aimed at 
reducing the circulating prostate specific antigen and the androgen level. This can be 
established by androgen deprivation therapy (ADT) and combined androgen blockade 
therapy (CAB).  
ADT includes:  
• Surgical castration - bilateral orchiectomy (removal of both the testes) and the 
standard castrate level of testosterone (≤ 20ng/dl) is achieved within 12hr.  
• Pharmacological castration using Gonadotropin releasing hormone (GnRH) 
receptor agonist or GnRH receptor antagonist. There will be an initial rise in the 
testosterone concentration by using GnRH receptor agonist but after 2 to 4 
weeks castration level of testosterone is maintained.  
CAB includes: 
• Pharmacological or surgical Castration. 
• Androgen receptor (AR) antagonists are used to prevent AR activation by 
dihydrotestosterone. There are two types of AR antagonist, steroidal and non-
steroidal. They competitively inhibit the binding of androgens to AR ligand 
binding pocket.  
• DHT synthesis inhibitors (Table 1). (Heidenreich et al., 2011). 
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Table 1:  Drugs used in prostate cancer treatment 
Hormonal therapy 
GnRH agonist                     Leuprolide, Goserilin, Triprorelin, Histrelin, Busrelin 
GnRH antagonist               Abarelix, Degarelix, Cetrorelix, Ganirelix 
Non-steroidal anti-androgens Flutamide, Bicalutamide, Nilutamide 
Steroidal anti-androgens Cyproterone acetate, Megesterol, Medroxyprogesterone 
DHT synthesis inhibitors Ketoconazole, Abiraterone acetate 
Non hormonal therapy 
Cytotoxic agents                 Docetaxel 
 
1.3. Prostate cancer targets 
1.3.1. AR mediated pathway    
 The normal development and maintenance of the prostate is dependent on 
androgen acting through the AR. AR remains important in the development and 
progression of prostate cancer. AR expression is maintained throughout prostate cancer 
progression, and the majority of androgen-independent or hormone refractory prostate 
cancers express mutated AR. Mutation of AR, especially mutations that result in a 
relaxation of AR ligand specificity, may contribute to the progression of prostate cancer 
and the failure of endocrine therapy. Similarly, alterations in the relative expression of 
AR co-regulators have been found to occur with prostate cancer progression and may 
contribute to differences in AR ligand specificity or transcriptional activity. Prostate 
cancer progression is also associated with increased growth factor production and an 
altered response to growth factors of prostate cancer cells.  (Heinlein et al., 2004). 
 Androgen action can be considered to function through an axis involving the 
testicular synthesis of testosterone, its transport to target tissues, and the conversion by 
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5- α reductase to the most active metabolite 5-dihydrotestosterone (DHT). Testosterone 
(TST) and DHT exert their biological effects through binding to AR and inducing AR 
transcriptional activity. The androgen-induced transcriptional activation of AR is 
modulated by the interaction of AR with co-regulators and by phosphorylation of AR 
and AR co-regulators in response to growth factors. (Heinlein  et al., 2002) (Buchanan 
et al., 2001).  Approximately 80 -90% of prostate cancers are dependent on androgen at 
initial diagnosis, and endocrine therapy of prostate cancer is directed toward the 
reduction of serum androgens and inhibition of AR. (Denis et al., 2000). 
The prostate specific antigen is the biological marker for androgen mediated 
prostate cancer. The prostate specific antigen (PSA) test clearly provides the 
opportunity for clinically relevant prostate cancer to be detected. However, in some 
patients the PSA test may lead to investigations which can identify clinically 
insignificant cancers, which would not have become evident in a man's lifetime. In 
addition, a raised PSA may often indicate benign prostatic enlargement, and this may 
provide an opportunity for treatment of this condition before complications develop.     
(Kirby et al., 2016).  
1.3.2. Estrogen receptor mediated pathway 
 Although AR signaling is the main molecular tool regulating growth and 
function of the prostate gland, estrogen receptor β (ER-β) is involved in the 
differentiation of prostatic epithelial cells and numerous anti-proliferative actions on 
prostate cancer cells. ER-β agonist is promising as an anticancer therapy and in the 
prevention of prostate cancer. (Paraskevi et al., 2014) 
1.3.3. Phosphoinositide 3-kinase (PI3K) pathway 
 The phosphoinositide 3-kinase (PI3K) pathway, a critical signal transduction 
system linking oncogenes and multiple receptor classes to many essential cellular 
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functions, is perhaps the most commonly activated signaling pathway in human cancer. 
Emerging evidence demonstrates a key role for the PI3K-AKT-mTOR signaling axis in 
the development and maintenance of Castration resistant prostate cancer. This pathway, 
which is deregulated in the majority of advanced Prostate cancer, serves as a critical 
nexus for the integration of growth signals to downstream cellular processes such as 
protein synthesis, proliferation, survival, metabolism and differentiation, thus providing 
mechanisms for cancer cells to overcome the stress associated with androgen 
deprivation.(Pixu et al., 2009)(Edlind et al.,2014). Studies suggest that 
PI3K/Akt/mTOR signaling is upregulated in 30-50% of prostate cancers, often through 
loss of PTEN. Molecular changes in the PI3K/Akt/mTOR signaling pathway have been 
demonstrated to differentiate benign from malignant prostatic epithelium and are 
associated with increasing tumor stage, grade, and risk of biochemical recurrence. 
(Todd et al., 2016). 
1.3.4. Bcl-2 over expression 
 The Bcl-2 family constitutes both agonists and antagonists of apoptosis that 
function at least in part through protein-protein interactions between various members 
of the family. The final outcome depends on the relative ratio of death agonists and 
antagonists. The Bcl-2 expression has been closely associated with the androgen 
independent phenotype of prostate cancer. Cytotoxic chemotherapy may be used as 
palliative therapy in androgen independent prostate cancer but has not been found 
effective. Most chemotherapeutic cytotoxic agents induce apoptosis in cancer cells by 
direct and indirect action on the cell cycle. In vitro and in vivo studies have established 
that the Bcl-2 expression confers an anti-apoptotic activity against androgen withdrawal 
and cytotoxic chemotherapy. It thus offers a tempting potential target for therapeutic 
manipulations of prostate cancer. The up-regulation of BCL-2 after androgen ablation 
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in prostate carcinoma cell lines and in a castrated-male rat model further established a 
connection between BCL-2 expression and prostate cancer progression. (Catz et al., 
2003) 
1.4. Cucurbitacin 
1.4.1. Phytochemistry 
 Cucurbitacins which are structurally diverse triterpenes with cucurbitane 
skeleton, found in the members of Cucurbitaceae and several other plant families 
possess immense pharmacological potential. They differ from most other tetracyclic 
triterpenes by being highly unsaturated and containing numerous keto-, hydroxyl- and 
acetoxy groups. Chemically, cucurbitacins are ranked according to the presence of 
various functional groups on rings A and C, diversity in the side chain and stereo-
chemical considerations. They are widely distributed in the plant kingdom, where they 
act as heterologous chemical pheromones that protect plants from external biological 
insults. Chemically, Cucurbitacins are ranked according to the presence of various 
functional groups on rings A and C, diversity in the side chain and stereochemical 
considerations. (Zheng  et al., 2007) 
1.4.2. Mechanism of anti-cancer activity 
 In general, cucurbitacins are considered to induce apoptosis by selectively 
inhibiting the JAK/STAT pathways. However, other mechanisms are also implicated in 
their apoptotic effects. These include the MAPK pathway, PARP cleavage, expression 
of active caspase-3, decreased pSTAT3 and JAK3 levels, as well as decreases in 
various downstream STAT3 targets such as Mcl-1, Bcl-2, Bcl-XL, and cyclin D3. All 
the above mentioned markers were implicated in apoptosis and the cell cycle control 
(Ríos et al., 2012). Being a triterpenoid, cucurbitacin might be a precursor of steroid. 
The structure of cucurbitacin resembles the structure of steroids. Approximately 80-
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90% of prostate cancers are dependent on androgen at initial diagnosis, and endocrine 
therapy of prostate cancer is directed toward the reduction of serum androgens and 
inhibition of AR (Heinlein et al., 2004).  
 The initial evidence of docking studies had revealed that the cucurbitacins have 
high binding for the AR. However, there has been no biological evidence to prove the 
same. Hence, in this study, we evaluated the prostate cancer activity of cucurbitacins by 
AR antagonism. Cucurbitacin is a novel compound for steroid dependent prostate 
cancer study. 
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2. LITERATURE REVIEW 
2.1. Role of AR in prostate cancer 
 The normal development and maintenance of the prostate is dependent on 
androgen acting through the AR. AR remains important in the development and 
progression of prostate cancer. AR expression is maintained throughout prostate cancer 
progression, and the majority of androgen-independent or hormone refractory prostate 
cancers express AR. Mutation of AR, especially mutations that result in a relaxation of 
AR ligand specificity, may contribute to the progression of prostate cancer and the 
failure of endocrine therapy by allowing AR transcriptional activation in response to 
anti-androgens or other endogenous hormones. Similarly, alterations in the relative 
expression of AR co-regulators have been found to occur with prostate cancer 
progression and may contribute to differences in AR ligand specificity or 
transcriptional activity. Prostate cancer progression is also associated with increased 
growth factor production and an altered response to growth factors by prostate cancer 
cells. The kinase signal transduction cascades initiated by mitogenic growth factors 
modulate the transcriptional activity of AR and the interaction between AR and AR co-
activators. The inhibition of AR activity through mechanisms in addition to androgen 
ablation, such as modulation of signal transduction pathways, may delay prostate 
cancer progression. (Heinlein et al., 2004) 
2.2. AR structure and functions 
 AR is a nuclear receptor encoded by a single gene located on human X-
chromosome at Xq11-12 region that spans more than 90kb and contains 8 exons. 
Human AR is a 900-920 amino acid containing protein and the variations are due to the 
polymorphism in the length of polyglutamine (CAG repeats) and polyglycine (GGN 
repeats) tracts of the first exon.  
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Like other nuclear receptors AR is also divided into 4 regions  
• Variable amino terminal domain or Activation function 1 (AF1),  
• DNA binding domain,  
• Hinge Region,  
• Ligand binding domain (LBD) / Activation function-2 (AF-2).  
Two isoforms of AR (A&B) are expressed in humans. AR-B isoform is predominantly 
expressed over AR-A isoform and the ratio of AR-B to AR-A isoform is 10:1 (Nigel et 
al., 2010).  
2.2.1. Structure and function of AR amino terminal domain  
 The amino terminal domain approximately contains half the molecule of AR 
and is required for full transcriptional activity.  The activity of AR depends on various 
transactivation units (TAU) within the amino terminal domain. The amino terminal 
domain of AR contains two transactivation units namely TAU-1 and TAU-5. TAU-1 
appears to be important in ligand dependant activation and TAU-5 is responsible for 
constitutive activation of AR. The 23FQNLF27 motif is involved in the ligand dependant 
intramolecular amino/carboxyl terminal interaction which is essential for full activation 
of AR because this interaction is essential for receptor stabilization, prevents ligand 
dissociation from AR, increases the DNA binding affinity, creates surface area for 
recruitment of co-activators etc. This ligand dependant amino/carboxyl terminal 
interaction occurs between the first motif of amino terminal domain with helices 3, 4 
and 12 of AF-2 domain overlapping the binding site of p160/SRC family of co-
activators (Scott et al., 2007). The second motif WXXLF is responsible for constitutive 
activation of AR in the absence of ligand or amino terminal domain. The 433WXXLF437 
motif interacts with LBD outside of AF-2 domain (Bin et al., 2000)  
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2.2.2. Structure and Function of AR DNA binding domain  
 DNA binding domain of AR is highly conserved and plays a major role in AR 
nuclear localization, receptor dimerization, specific and non-specific DNA binding. 
DNA binding domain is made of 3 α-helices having 2 zinc finger motifs and a short C- 
terminal extension. Each zinc finger consists of 4 cysteine residues and a Zn-1 ion. The 
first zinc finger (P-box) is involved in the sequence recognition and directly binds to 
major groove of hormone response element (HRE) in the DNA. The second zinc finger 
(D-box) is involved in the stabilization of DNA bound AR interactions and mediate 
DNA dependant intermolecular protein-protein interactions (homo dimerization) (Scott 
et al., 2007). 
 In AR the carboxy terminal extension amino acids provide an additional dimer 
interface along with second zinc finger that is required for selective and high affinity 
binding of AR to specific androgen response elements (Edward et al., 2002). 
2.2.3. Structure and functions of hinge region 
 Hinge region is flexible and separates the DNA binding domain from Ligand 
binding domain. The hinge region of AR has a transcriptional inhibiting motif made of 
highly basic amino acids and has an attenuating effect on AF-2 by interfering with the 
recruitment of co-activators. Deletion of the inhibiting motif enhances the 
intramolecular N/C terminal interaction which is necessary for AR transcriptional 
function as discussed in Variable amino terminal domain but impairs the hormone 
dependant nuclear translocation because of the deletion of nuclear localization signal 
and also affects DNA binding and receptor stability (Annemie et al., 2007). 
 
 
 
                      Literature review 
 
Department of Pharmacology, PSGCOP Page 11 
 
2.2.4. Structure and function of LBD 
 The LBD of AR consists of 12 α-helices and 1 β-sheet that fold to form triple 
layered α-helical sandwich which creates a hydrophobic ligand binding pocket in which 
ligand binds (Fig.1). 
 Agonist binding to LBD causes helix-12 to lay over the ligand binding pocket 
and exposes the groove necessary for intramolecular N/C interaction. Antagonist 
binding displaces the helix-12 away from ligand binding pocket and unveils the binding 
surface for co-repressor NcoR/SMRT interaction and inhibition of AR transcriptional 
activity. (Osguthorpe et al., 2011). 
Fig. 1: Crystal structure of wild AR showing α-helices and β-strand folding 
 
Fig 2: Essential Hydrogen bond interactions of DHT 
 
 
                      Literature review 
 
Department of Pharmacology, PSGCOP Page 12 
 
2.2.5. Ligand dependant AR activation  
 The ligand dependant activation is required for maximum activation of full 
length AR. Upon androgen binding to AR LBP, AR dissociates from heat shock 
proteins (HSP), undergoes ligand dependant intramolecular amino-carboxy terminal 
interaction, phosphorylation, nuclear translocation, DNA dependant homodimerization, 
co-activator recruitment, binding to specific androgen response elemnts and initiation 
of transcription. AR resides predominantly in cytoplasm is associated with HSP and 
chaperons. HSP also have active role in transcriptional activation of the receptor 
because HSP 90 binds to AR LBD and keeps it in an active conformation so that AR is 
able to bind androgens. Androgen binding to LBP results in the dissociation of HSP 
from AR, helix 12 to fold over the LBP to enclose the ligand unmasking the necessary 
grooves to form intramolecular amino-carboxy terminal interaction, dimerization and 
exposes nuclear localization signal. Phosphorylation of AR also plays an important role 
in transcriptional activity of AR. The newly translated AR is phosphorylated at serine 
residues 506, 641, 653 as a post-translational modification which increase the ligand 
acquiring properties. Antagonist binding does not enhance receptor phosphorylation. 
After translocation into nucleus AR undergoes DNA dependant intermolecular 
homodimerization (Jin et al., 2009). 
Table 2: Drugs available for prostate cancer 
S. No Drug Classification 
1. Bicalutamide Anti-androgen 
2. Enzalutamide Anti-androgen 
3. Flutamide Anti-androgen 
4. Nilutamide Anti-androgen 
5. Cyproterone acetate Anti-androgen 
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6. Abiraterone acetate Anti-androgen and CYP17A1 inhibitor 
7. Cabazitaxel Taxane derivative and anti-microtubular agent 
8. Docetaxel Taxane derivative and anti-microtubular agent 
9. Degarelix Testosterone inhibitor 
10. Goserelin acetate LHRH agonist 
11. Leuprolide acetate LHRH agonist 
12. Triprorelin acetate LHRH agonist 
13. Mitoxantrone hydrochloride Anti-tumor antibiotic 
14. Sipulencel – T Cellular immunological agent 
15. Histrelin  GnRH inhibitor 
16. Buserelin acetate GnRH inhibitor 
17. Ketoconozole Inhibitor of CYP17 and TST synthesis 
18. Radium 223 dichloride Radiopharmaceutical 
19. Prednisone Corticosteroid 
20. Hydrocortisone Corticosteroid 
21. Dexamethasone Corticosteroid 
22. Denosumab Monoclonal antibody 
23. Zoledonic acid Bisphosphonate 
Ref: (National cancer institute) (Gerald  et al., 2017) 
Table 3: Drugs  in clinical trial for prostate cancer 
S. No Drug Phase 
1. Vaccine-Based Immunotherapy Regimen (VBIR) I 
2. AZD8186 I 
3. ZEN003694 I 
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4. Abiraterone Acetate With or Without Cabazitaxel  II 
5. ARN-509+Abiraterone acetate+Leuprolide with Stereotactic, Ultra-
Hypofractionated Radiation  
II 
6. JNJ-56021927 in Combination with Abiraterone Acetate and 
Prednisone Versus Abiraterone Acetate and Prednisone in Subjects 
with Chemotherapy-naive Metastatic Castration-resistant Prostate 
Cancer 
III 
Ref: (Memorial Sloan Kettering cancer centre, 2017)  
2.3. The role of ER-β in prostate cancer 
 ER-β is encoded by chromosome locus 14q22–24 and it is expressed in both 
stromal and luminal epithelial cells of the human prostate. ERα is expressed mainly in 
prostate stroma. (Fixemer et al., 2003). As a member of the nuclear receptor family, 
ERβ acts individually, forming homodimers (ERβ/β) or heterodimers (ERβ/α). Ligand-
induced dimerization leads to translocation of dimer to the nucleus, binding with co-
regulatory proteins and interaction with responsive elements (binding sites) in the 
promoter regions including nuclear factor-κB (NF-κB) and activator protein 1 (AP-1). 
ERβ binds indirectly to these alternative binding sites through the recruitment of 
cofactors to the receptor. (Heldring et al., 2007). However, less is known about the 
interactions between ERβ and transcriptional cofactors. ERβ/β and ERα/β homo- and 
hetero dimers, respectively, exhibit anti-proliferative effects as they activate different 
target genes. Interestingly, ERα/β heterodimer is more stable than the ERβ/β 
homodimer. Overall, ER dimerization is a crucial step in defining ER signaling. 
Interestingly, prostate morphogenesis occurs under the control of androgens and 
is modulated by estrogens (Marker et al., 2003). However, ERβ is not required in early 
stages of prostate development, as it appears to be expressed in the prostate after 2 wks 
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in the life of newborn mice following ERα expression (Omoto et al., 2005). Moreover, 
in the developing rodent prostate gland, ERα-induced excessive estrogenic exposure 
leads to permanent alternation of the gland including squamous metaplasia, 
inflammation and epithelial dysplasia as reported by an in utero study (Prins et al., 
2006). Notably, the developmental pattern for ERβ in the human prostate is different 
from the rodent. Apparently, ERβ is the only detectable ER in the developing human 
fetal prostate. However, by year 11 post-natally, expression of ERβ is restricted to the 
basal epithelial cells and prostate stromal compartments, similar to adult human 
prostate. (Shapiro et al.,2005). Thus, in the developing human prostate, ERβ is the 
predominant ER in both stromal and epithelial cells (Adams et al., 2002). 
 In the adult human prostate, ERβ is characterized as an important mediator of 
epithelial differentiation (Imamov et al., 2004). The mechanisms through which ERβ 
maintain differentiation involve the degradation of hypoxia-inducible factor 1α (HIF-
1α) (Mak et al., 2010). ERβ enhances transcription of prolyl hydroxylase domain-
containing protein 2 (PHD2) that hydroxylates HIF-1α and marks HIF for destruction 
by the von Hippel-Lindau tumor suppressor (VHL) (Mak et al., 2013). Additionally, 
ERβ appears to have antiproliferative actions which are independent from the 
alternations of systemic androgen concentration and the activation of ERα, as 
documented in aromatase-knockout mice treated with ERβ-specific agonists 
(McPherson et al., 2007). There, ERβ seemed to have a suppressive role in the 
proliferation process, stimulating the differentiation of adult prostate epithelial cells. 
 
2.4. Role of Bcl-2 protein family in regulation of apoptosis in prostate cancer 
In-vitro studies have highlighted the role of Bcl-2 proteins as important 
regulators of the apoptotic pathway in several cell types Bcl-2, the prototype of this 
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family, was discovered by studies of t(14:18) chromosomal translocations, which are 
frequent in non-Hodgkin lymphomas and follicular lymphomas. The name Bcl-2 (B 
cell lymphoma/leukemia gene2) signifies the close association of this gene to these 
malignancies in which enhanced expression was initially believed to arise solely as a 
result of these translocations, resulting in the juxta-position of the Bcl-2 gene to a 
potent enhancer element sequence of the Ig H gene. Several genes have been identified 
and designated as the Bcl-2 family based on their sequence homology to Bcl-2. These 
genes include both positive and negative regulator of apoptosis.(Chaudhary et al.,1999) 
2.5. Role of  PI3K/Akt/mTOR pathway in prostate cancer 
 One pathway with a prominent role in prostate cancer is the PI3K/Akt/mTOR 
pathway. Current estimates suggest that PI3K/Akt/mTOR signaling is upregulated in 
30-50% of prostate cancers, often through loss of PTEN. Molecular changes in the 
PI3K/Akt/mTOR signaling pathway have been demonstrated to differentiate benign 
from malignant prostatic epithelium and are associated with increasing tumor stage, 
grade, and risk of biochemical recurrence. Multiple inhibitors of this pathway have 
been developed and are being assessed in the laboratory and in clinical trials, with 
much attention focusing on mTOR inhibition. Current clinical trials in prostate cancer 
are assessing efficacy of mTOR inhibitors in combination with multiple targeted or 
traditional chemotherapies, including bevacizumab, gefitinib, and docetaxel. (Todd et 
al., 2009) 
 
2.6. Caspase pathway 
 Caspases involved in apoptosis have been subclassified by their mechanism of 
action and are either initiator caspases (caspase-8 and -9) or executioner caspases 
(caspase-3, -6, and -7). (David et al., 2013). Initiator caspases activate executioner 
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caspases that subsequently coordinate their activities to demolish key structural proteins 
and activate other enzymes.   
 The extrinsic apoptosis pathway is activated through the binding of a ligand to a 
death receptor, which in turn leads, with the help of the adapter proteins 
(FADD/TRADD), to recruitment, dimerization, and activation of caspase-8. Active 
caspase-8 then either initiates apoptosis directly by cleaving and thereby activating 
executioner caspase (-3, -6, -7), or activates the intrinsic apoptotic pathway through 
cleavage of BID to induce efficient cell death. The intrinsic or mitochondrial apoptosis 
pathway can be activated through various cellular stresses that lead to cytochrome c 
release from the mitochondria and the formation of the apoptosome, comprised of 
APAF1, cytochrome c, ATP, and caspase-9, resulting in the activation of caspase-9. 
Active caspase-9 then initiates apoptosis by cleaving and thereby activating executioner 
caspases (Fig 3). 
Fig 3: Caspase pathway 
 
 
2.7. Cucurbitacin 
 Cucurbitacins are found in many of the cucurbitaceous plants (Kaushik et al., 
2015). This diverse group of compounds may prove to be important lead molecules for 
future research. Research focused on these unattended medicinal leads from the nature 
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can prove to be of immense significance in generating scientifically validated data with 
regard to their efficacy and possible role in various diseases. Medicinal and toxic 
properties of these compounds have stimulated a continuing interest in them. (Kupchan 
et al., 1978). Many genus of Cucurbits viz. Trichosanthes, Cucurbita, Cucumis and 
Citrullus are affluent in cucurbitacins. These compounds have also been discovered in 
other plant families like Scrophulariaceae, Cruciferae, Datiscaceae, Primulaceae, 
Rubiaceae etc. The diversity of cucurbitacins lies in variety of its side chain derivatives 
that contribute to their disparate pharmacological actions. (Stuppner et al., 1993). The 
bitter taste of plant species like cucumber has been attributed to the presence of 
cucurbitacins.  
 The first cucurbitacin was isolated as a crystalline substance in 1831 and was 
named α-elaterin. Certain plant species rich in cucurbitacins like Momordica hold 
coveted position in different system of traditional medicines for curative effects in 
metabolic disease like diabetes. All cucurbitacins contain a basic 19-(10→9β)-abeo--
10α-lanost-5--ene ring skeleton. A common feature among all compounds in the 
category of Cucurbitacins is the presence of 5, (6) --double bond. The difference of 
Cucurbitacins from steroidal nucleus lies in the fact that in basic structure of 
Cucurbitacins a methyl group is located at C-9 rather than C-10. (Dinan, et al., 2001) 
Most of the Cucurbitacins are tetracycline, but some representatives have an extra ring 
due to formal cyclization between C--16 and C--24 as in cucurbitacins S and T. 
(Gamlath et al., 1998) The Cucurbitacins differ from most of the other tetracyclic 
triterpenes by being highly unsaturated and contains numerous keto--, hydroxyl--, and 
acetoxy--groups. (Jorn et al., 1998) Certain Cucurbitacins have been discovered in the 
form of glycosides and some of them lack C--11 carbonyl function (Stuppner et al., 
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1991). Cucurbitacin B inhibits ATP citrate lyase which is a key enzyme that plays 
crucial role in cancer cell metabolism in prostate cancer (Gao et al., 2014).  
 The structural composition of following Cucurbitacins are known and have been 
designated by the letters: A, B, C, D, E, F, G, H, I, J, K, L, O, P, Q, R and S.  
Cucurbitacin I caused reduction of growth in breast and prostate carcinoma cell lines 
(MDA-MB-231, MDA-MB-468, Panc-1), in vitro, as well as in nude mice xenograft 
models (Sun et al., 2008). Cucurbitacin Q induces apoptosis more potently in human 
and murine tumors. Furthermore, in HeLa cells, cucurbitacins inhibited DNA, RNA, 
and protein synthesis (Witkowski et al., 1984). The 23, 24-dihydrocucurbitacin B and 
cucurbitacin R, inhibit proliferation and/or induce apoptosis in colon cancer cell lines. 
Cucurbitacin E inhibits the proliferation of prostate cancer cells and caused disruption 
of the cytoskeleton structure of actin and vimentin (Duncan et al., 1996). Cucurbitacin 
A and I act by inhibition of only JAK2 and STAT3 respectively. It has been reported 
that cucurbitacin E inhibited tumor angiogenesis by inhibiting JAK-STAT3 and 
mitogen activated protein kinases (MAPK) signaling pathways. It has been reported 
that cucurbitacin B exerts an anticancer effect by inhibiting telomerase via down-
regulating both the human telomerase reverse transcriptase and c-Myc expression in 
breast cancer cells (Kaushik et al., 2015). 
2.7.1. Cucurbitacin and Anti-inflammatory activity 
Cucurcitacin analogues viz. Cucurbitacin R and DHCB have been reported to 
possess anti-inflammatory potential and their action is reported to be mediated by 
inhibition of tumor necrosis factors (TNF)-α and other mediators of inflammation such 
as nitric-oxide synthase-2 and cyclo-oxygenase-2 (Escandell et al.,2008). Cucurbitacins 
B, D, E and I have been reported to inhibit cyclo-oxygenase -2 enzymes with no effect 
on COX-1 enzymes. (Jayaprakasam et al.,2003). The anti-inflammatory response of 23, 
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24-dihydrocucurbitacin D (DHCD) have been hypothesized to get mediated through 
blocking of NF-κ B activation thereby obstructing the release of nitrous oxide. DHCD 
can be taken up as probable lead and appraised for providing a promising anti-
inflammatory agent. (Park et al., 2004 ). 
2.7.2. Cucurbitacin and Antitumor activity 
Very less information is available on the role of Cucurbitacins at molecular 
level which has lead to slow advancement in the development of Cucurbitacins as anti-
cancer agents. (Kee et al., 2008). In relation to cancer, targets of Cucurbitacin actions 
involve growth inhibition, arrest of cell cycle at G2/M phase and induction of apoptosis 
in cancer cell. (Liu et al., 2000). The mechanisms underlying anti-tumorigenic 
potentials of Cucurbitacins involve inhibition of Janus kinase/Signal Transducer 
Activator of Transcription 3 (JAK/STAT3) signaling pathway whose activation is 
required for the proliferation and sustainment of cells. (Bowman et al., 2000). The role 
of Cucurbitacin I in suppressing phosphotyrosine STAT3 in cancer cell lines and 
cancerous lung cells of humans has been reported. (Blaskovich et al., 2003). Although 
Cucurbitacin B, E, and I act by inhibiting the activation of both JAK2 and STAT3, 
Cucurbitacin A and I acts by inhibition of only JAK2 and STAT3 respectively. (Sun et 
al., 2005). It has been reported that Cucurbitacin E inhibited tumor angiogenesis by 
inhibiting JAK-STAT3 and mitogen activated protein kinases (MAPK)- signaling 
pathways (Dong et al., 2010). The role of interference with actin cytoskeleton has been 
attributed to anti-proliferative effects of Cucurbitacin B and E. The anti-proliferative 
activities have been correlated directly with the disruption of the F-actin cytoskeleton. 
(Duncan et al., 1996). It has been proposed that the combination of Cucurbitacin B with 
docetaxel may augment the chemotherapeutic effects by suppression STAT3 in patients 
with laryngeal cancer. (Liu et al., 2000). It is expected that cucumber fruits have anti-
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tumor effects since they have been reported to contain Cucurbitacin C. (Higashio et al., 
2002) It has been reported that cucurbitacin B exerts an anticancer effect by inhibiting 
telomerase via down-regulating both the human telomerase re verse transcriptase and c-
Myc expression in breast cancer cells. (Duangmano et al., 2010) 
2.7.3. Cucurbitacin and Anti-artherosclerotic activity 
There have been reports on Cucurbitacin B and E in glycosidic form to exhibit 
inhibitory effect on lipid oxidation products like- malonaldehyde (MDA) and 4-
hydroxynonenal (4-HNE). (Tannin-Spitz et al.,2007). These reports bolster the 
therapeutic role of Cucurbitacins in artherosclerosis, which involves modification of 
lipoproteins by involvement of- MDA and 4-HNE. (Saba et al., 2010) 
2.7.4. Cucurbitacin and Anti-diabetic activity 
There have been a plethora of reports on the role of Cucurbitacins for their 
cytotoxic, hepatoprotective, cardiovascular, and antidiabetic effects. (Park et al., 2004). 
Cucurbitane triterpenoids present in momordica fruits are noted for antidiabetic and 
anticancer activities, this may provide leads as a class of therapeutics for diabetes and 
obesity. (Tan et al., 2008). The 5’-adenosine monophosphate-activated protein kinase 
(AMPK) pathway is suggested as a probable mechanism for the stimulation of GLUT4 
translocation by triterpenoids from M. charantia. It is particularly interesting in relation 
to diabetes and obesity because activation of AMPK increases fatty acid oxidation, 
inhibits lipid synthesis, and can improve insulin action. An analogue of 23,24-
dihydrocucurbitacin F from Hintonia latiflora has been reported to possess significant 
hypoglycemic and antihyperglycemic effects. The probable mechanism underlying-- 
antihyperglycemic effect could be stimulation of insulin release and regulation of 
hepatic glycogen metabolism. (Jose et al., 2007) 
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2.7.5. Miscellaneous activity of cucurbitacin 
It has been reported that the concentration of Cucurbitacin C in the leaves is an 
important parameter in spider mite resistance in Cucumis sativus, perhaps by acting as 
an antagonist of a spider mite ecdysteroid receptor. (Balkema et al., 2003). The steroid 
like resemblance of Cucurbitacin D may possess therapeutic effects via inhibition of 
Na+/K+-ATPase. (Chen et al.,2010). The role of Cucurbitacins as preventive and radical 
scavenging antioxidant has also been reported. Cucurbitacins have also been reported to 
possess adaptogenic activity. Cucurbitacins have been reported to increase the rat 
capillary permeability and to demonstrate antifertility effects in female mice. (Shohat et 
al.,1972). Cucurbitacin D has been reported to inhibit ovulation in mice. There has been 
protective role of Cucurbitacins acting as allomones in many plant species. Role of 
Cucurbitacins as anti-feedants for few insects, birds and as kairomones (Cucurbitacin 
B, E, D, I and L) for diabroticite beetles have been reported. (Subbiah. 2011). It is 
reported that Cucurbitacins act via Cuc receptors located on the maxillary palpi. They 
arrest the searching behavior of diabroticite beetles and produce a compulsive feeding 
behavior. Role of Cucurbitacin B and D in controlling diabrotic beetles can be an 
interesting approach. (Escandell et al.,2007). 
2.7.6. Cucurbitacin I (JSI-124) induces apoptosis via p53 pathway in HepG2 cells 
 JSI-124 inhibited the proliferation and induced Hoechst 33258-stained 
chromatin condensation in HepG2 cells in a concentration- and time-dependent manner. 
Flow cytometry revealed that 1.00 µmol/L JSI-124 treatment increased the apoptotic 
rate significantly in HepG2 cells compared with the control cells. Furthermore, JSI-124 
significantly enhanced the mRNA expressions of p53 and its downstream apoptotic 
factors, including Bax and Fas, but did not change the gene expression of the p53 tumor 
suppressor, MDM2. The 48-hour treatment of JSI-124 in HepG2 cells significantly 
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increased the levels of p53 and cleaved caspase-3 proteins. Conclusion JSI-124 induces 
the apoptosis of HepG2 cells through the activation of p53 and its downstream pro-
apoptotic factors. (Wu et al., 2017) 
Cucurbitacin I dose- and time-dependently inhibited the proliferation of five OS 
cell lines. Following cucurbitacin I treatment, STAT3 was inactivated and analysis of 
Mcl-1, cleaved PARP and caspase-3 indicated apoptosis induction. Expression of cell 
cycle regulator proteins, such as phospho-cyclin D1, c-Myc and survivin, were 
suppressed. Finally, cucurbitacin I potently inhibited the tumor growth of human OS 
143B cells in nude mice. In-vitro and in-vivo results suggest that STAT3 inhibition by 
cucurbitacin I will be an effective and new approach for the treatment of Osteosarcoma. 
(Oi et al., 2016 ) 
2.7.7. Cucurbitacin I and cardio-toxicity 
 The mechanisms of cucurbitacin-I-induced cardiotoxicity are examined by 
investigating the role of MAPK-autophagy-dependent pathways. After being treated 
with 0.1-0.3µM cucurbitacin-I for 48h, H9c2 cells showed a gradual decrease in the cell 
viabilities, a gradual increase in cell size, and mRNA expression of ANP and BNP 
(cardiac hypertrophic markers). Cucurbitacin-I concentration-dependent apoptosis of 
H9c2 cells was also observed. The increased apoptosis of H9c2 cells was paralleling 
with the gradually strong autophagy levels. Furthermore, an autophagy inhibitor, 3-
MA, was used to block the cucurbitacin-I-stirred autophagy, and then the hypertrophy 
and apoptosis induced by 0.3µM cucurbitacin-I were significantly attenuated. In 
addition, cucurbitacin-I exposure also activated the MAPK signaling pathways, 
including ERK1/2, JNK, and p38 kinases. Interestingly, only the ERK inhibitor U0126, 
but not the JNK inhibitor SP600125 and p38 MAPK inhibitor SB203580, weakened the 
induction of 0.3µM cucurbitacin-I in hypertrophy, autophagy and apoptosis. The 
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findings suggest that cucurbitacin-I can increase the autophagy levels of H9c2 cells, 
most likely, through the activation of an ERK-autophagy dependent pathway, which 
results in the hypertrophy and apoptosis of cardiomyocytes. (Wu et al., 2016 ) 
2.7.8. Mechanism of cucurbitacin I in gastric cancer cells 
 Deng et al., for the first time systematically studied the underlying molecular 
mechanisms of Cu-I-induced gastric cancer cell death both in vitro and in vivo. In this 
study, they show that Cu-I markedly inhibits gastric cancer cell growth by inducing 
G2/M phase cell cycle arrest and apoptosis at low nanomolar concentrations via a 
STAT3-independent mechanism. Notably, Cu-I significantly decreases intracellular 
GSH/GSSG ratio by inhibiting NRF2 pathway to break cellular redox homeostasis, and 
subsequently induces the expression of GADD45α in a p53-independent manner, and 
activates JNK/p38 MAPK signaling. Interestingly, Cu-I-induced GADD45α and 
JNK/p38 MAPK signaling form a positive feedback loop and can be reciprocally 
regulated by each other. Therefore, the present study provides new insights into the 
mechanisms of antitumor effects of Cu-I, supporting Cu-I as an attractive therapeutic 
drug in gastric cancer by modulating the redox balance. (Deng et al., 2016) 
 
2.7.9. Cucurbitacin I and Breast cancer 
 Qi et al used JSI-124 (Cucurbitacin I), a selective JAK/STAT3 signaling 
pathway inhibitor, to investigate the role of STAT3 in tumor angiogenesis of a human 
BC cell line in vitro. JSI-124 inhibited cell viability, proliferation, adhesion, migration 
and tube formation of a human BC cell line MDA-MB-468. After transfection with 
pMXs-Stat3C, a dominant active mutant, the inhibitory effects of JSI-124 on MDA-
MB-468 were abolished. Furthermore, JSI-124 reduced the phosphorylation of STAT3. 
These results suggested that JSI-124 inhibited tumor angiogenesis of the human BC cell 
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line in vitro through the reduction of STAT3 phosphorylation. In addition, JSI-124 
could reduce VEGF transcription and secretion, suggesting that JSI-124 is also 
involved in the inhibition of the VEGF autocrine loop in the tumor microenvironment. 
(Qi et al., 2015) 
The small GTPase Rac1 has been widely implicated in mammary tumorigenesis 
and metastasis. Previous studies established that stimulation of ErbB receptors in breast 
cancer cells activates Rac1 and enhances motility via the Rac-guanine nucleotide 
exchange factor P-Rex1. As the Janus tyrosine kinase 2 (Jak2)/signal transducer and 
activator of transcription 3 (Stat3) pathway has been shown to be functionally 
associated with ErbB receptors, Lopez et al asked if this pathway could mediate P-
Rex1/Rac1 activation in response to ErbB ligands. They found that the anticancer agent 
cucurbitacin I, a Jak2 inhibitor, reduced the activation of Rac1 and motility in response 
to the ErbB3 ligand heregulin in breast cancer cells. However, Rac1 activation was not 
affected by Jak2 or Stat3 RNA interference, suggesting that the effect of cucurbitacin I 
occurs through a Jak2-independent mechanism. Cucurbitacin I also failed to affect the 
activation of P-Rex1 by heregulin. Subsequent analysis revealed that cucurbitacin I 
strongly activates RhoA and the Rho effector Rho kinase (ROCK) in breast cancer cells 
and induces the formation of stress fibers. Interestingly, disruption of the RhoA-ROCK 
pathway prevented the inhibitory effect of cucurbitacin I on Rac1 activation by 
heregulin. Lastly, they  found that RhoA activation by cucurbitacin I is mediated by 
reactive oxygen species (ROS). The ROS scavenger N-acetyl L-cysteine and the 
mitochondrial antioxidant Mito-TEMPO rescued the inhibitory effect of cucurbitacin I 
on Rac1 activation. In conclusion, these results indicate that ErbB-driven Rac1 
activation in breast cancer cells proceeds independently of the Jak2 pathway. Moreover, 
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they established that the inhibitory effect of cucurbitacin I on Rac1 activity involves the 
alteration of the balance between Rho and Rac. (Lopez et al., 2013) 
2.7.10. Cucurbitacin I and colon cancer 
Song et al., examined the chemopreventive potential of cucurbitacin I, a natural 
component extracted from plants of the Cucurbitaceae family, in the colon cancer cell 
line COLO205. They hypothesized that cucurbitacin I would prevent colon cancer cell 
migration and invasion, and sensitize colon cancer cells to chemotherapy. The data 
demonstrated that exposure of the COLO205 cells to cucurbitacin I significantly 
decreased cell viability. Furthermore the data demonstrated for the first time that in the 
COLO205 cells, cucurbitacin I could suppress the cell migration and invasion, and 
harbor chemosensitization activity against colon cancer. The anticancer activity of 
cucurbitacin I was accomplished by downregulating p-STAT3 and MMP-9 expression. 
Collectively, the results suggest that cucurbitacin I may be a potent adjuvant 
chemotherapeutic agent for colon cancer with anti-migration, anti-invasion and 
chemosensitizing activities. (Song et al., 2015). Cucurbitacin-I reduced colon cancer 
cell proliferation by enhancing apoptosis and causing cell cycle arrest at the G2/M 
phase. (Kim et al., 2014).  
 
Table 4: Cucurbitacins and their activity 
Cucurbitacin Structure Activity Reference 
A 
 
No reported 
biological activity 
found. 
 
 
 
----- 
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B 
 
Anti-proliferative 
activity in prostate 
and breast cancer.  
Gao et 
al.,2014. 
Duangmano  et 
al.,2010. 
C 
 
No reported 
biological activity 
found. 
 
 
 
----- 
D 
 
 Inhibits proliferation 
and induce apoptosis 
of T-cell leukemia 
cells correlating NF-
κB inhibition and 
down-regulation of 
the expression of 
antiapoptotic proteins 
Bcl-xL and Bcl-2 
Ding et 
al.,2011 
E 
 
Cucurbitacin E-
induced disruption of 
the actin and vimentin 
cytoskeleton in 
prostate carcinoma 
cells and inhibits 
tumor angiogenesis 
through VEGFR2 
mediated JAK2/ 
STAT3 signaling 
pathway. 
Duncan et al., 
1996. 
 Dong et al., 
2010. 
F 
 
Cucurbitacin F 
induces cell cycle 
G2/M arrest and 
apoptosis in human 
soft tissue sarcoma 
cells. 
Lohberger et 
al., 2015. 
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G 
H 
I 
J 
K 
L 
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No reported 
biological activity 
found. 
 
 
 
-----
 
No reported 
biological activity 
found. 
 
 
 
-----
 
Anti-tumor activity 
against colon cancer, 
gastric cancer, 
osteosarcoma breast 
cancer. 
Deng 
al.,
Qi 
Ren 
al.,
et al.,
Kim 
2014.
al.,
 
No reported 
biological activity 
found. 
 
 
 
-----
 
No reported 
biological activity 
found. 
 
 
 
-----
 
No reported 
biological activity 
found. 
 
 
 
-----
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et 
2016,  
et al.,2015, 
et 
2014, Song 
2015. 
et al 
 Oi et 
2016. 
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O 
 
No reported 
biological activity 
found. 
 
 
 
----- 
P 
 
No reported 
biological activity 
found. 
 
 
 
----- 
Q 
 
Selective STAT3 
activation inhibitor 
with potent antitumor 
activity 
Sun et al., 
2008. 
R 
 
Reduces the 
inflammation and 
bone damage 
associated with 
adjuvant arthritis in 
Lewis rats by 
suppression of tumor 
necrosis factor-alpha 
in T lymphocytes and 
macrophages. 
Escandell et 
al., 2007. 
S 
 
No reported 
biological activity 
found. 
 
 
 
----- 
U 
 
No reported 
biological activity 
found. 
 
 
 
----- 
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3. OBJECTIVES AND PLAN OF STUDY 
3.1 Objectives 
 To identify Cucurbitacin derivative, which is having high affinity towards 
prostate cancer targets by in-silico method. 
 To evaluate the cytotoxic activity of the cucurbitacin derivative in prostate 
cancer cell lines by MTT assay. 
 To elucidate the apoptotic mechanism of cucurbitacin in prostate cancer cell line 
by caspase assay, acridine orange\ethidium bromide staining methods and gene 
expression studies. 
 
3.2 PLAN OF STUDY 
3.2.1 Phase І 
3.2.1.1 In-Silico study 
 In-silico study comprises of molecular docking of cucurbitacin derivatives (A – 
U) with prostate cancer target proteins like AR, ER-β, PI3K-α, Bcl2 and AKT. 
 Cucurbitacin which is having Glide score more than the standard in concerned 
protein will be studied further. 
 Selected cucurbitacins will be examined in QikProp for its ADME properties 
and toxicity. 
 One lead molecule will be taken for in-vitro studies in cancer cell lines. 
3.2.2 Phase ІІ 
3.2.2.1 In-Vitro study   
 Culturing LNCaP and PC3 cell lines using RPMI + 10% FBS and DMEM + 
10% FBS respectively in 5% CO2 at 37˚ C. 
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 MTT assay of standard bicalutamide and cucurbitacin will be done in LNCaP 
and PC3 cell lines to evaluate the IC50 value.  
 Determination of apoptosis mechanism by ethidium bromide/acridine orange 
staining method and caspase 3, 8, 9 assay. 
 PCR studies – to detect the expression of genes such as Bax, Bcl2 and PSA 
(Prostate Specific Antigen). 
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4. MATERIALS AND METHODS 
4.1. Materials 
4.1.1. Chemicals used in this study 
Table 5: Chemicals used for this study 
S. No Chemical Manufacturer 
1. Cucurbitacin I Phytolab 
2. DMSO Thermo fisher scientific 
3. DMEM Gibco 
4. RPMI Gibco 
5. Trypsin Sigma 
6. Phosphate buffer saline Gibco 
7. FBS Sigma 
8. MTT Himedia 
9. Dihydrotestosterone Himedia 
10. Bicalutamide Santa cruz 
11. Acridine orange  Himedia 
12. Ethidium bromide Himedia 
13. Caspase 3 assay kit Biovision 
14. Caspase 8 assay kit Biovision 
15. Caspase 9 assay kit Biovision 
16. TRI reagent Sigma 
17.  Chloroform Nice chemicals 
18.  High capacity cDNA conversion kit Applied biosystems 
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Table 6: Instruments used in this study 
S. No Instruments Manufacturer 
1. Glide Schrodinger 
2. Biosafety working hood Esco  
3. CO2 incubator Thermo scientific 
4. ELISA reader Multiskan Go – Thermo scientific 
5. Autoclave sterilizer Everflow autoclave 
6. Refrigerated centrifuge Thermo scientific  
7. Deep freezer Thermo scientific 
8. Inverted fluorescence microscope Nikon 
9. Arthik thermal cycler Thermo scientific 
10. Micropipettes Eppendorf 
11. Gel doc image analyser Syngene 
12. Microcentrifuge Eppendorf 
 
4.2. Methods 
4.2.1.  In-silico screening 
4.2.1.1. Molecular Modelling 
 The cucurbitacin derivatives are downloaded from the PubChem compound 
database and are prepared for docking using LigPrep (Ligprep, Schrödinger). LigPrep 
helps to convert 2D structure to 3D representation. LigPrep can also produce a number 
of structures from each input structure with various ionization states, tautomers, 
stereochemistries, and ring conformations, and eliminate molecules using various 
criteria including molecular weight or specified numbers and types of functional groups 
           Materials and methods 
 
Department of Pharmacology, PSGCOP Page 34 
 
present. Subsequently the structures were optimized by means of OPLS-2005 using a 
default setting in LigPrep. 
4.2.1.2. Protein preparation 
 Proteins used in the study are downloaded from the RCSB protein data bank 
(PDB). Protein structures are prepared by using Maestro software (Maestro, 
Schrödinger) and aligned using the protein structure alignment module in Prime (Prime, 
Schrödinger). Bond order and formal charges were added for heterogroups and 
hydrogens were added to all atoms in the system. Protein was inspected visually for 
accuracy in the χ2 dihedral angle of Asn and His residues and the χ3 angle of Gln, and 
rotated by 180˚ when needed to maximize hydrogen bonding. The proper His tautomer 
was also manually selected to maximize hydrogen bonding. All Asp, Gln, Arg and Lys 
residue were left in their charged state. Water molecules for crystallization were 
removed from the complex except in the active site. A brief relaxation was performed 
on structure using the protein preparation module in Maestro with the “Refinement 
only” option. This is a two – part procedure that consists of optimizing hydroxyl and 
thiol torsion in the first stage followed by an all-atom constrained minimization carried 
out with the impact refinement module (Impref) using the OPLS-2005 force field to 
alleviate steric clashes that may exist in the original PDB structures. The minimization 
was terminated when the Root Mean Square Deviation (RMSD) reached a maximum 
cutoff of 0.30 Å. 
4.2.1.3. Grid generation and ligand docking 
 Grids were defined by centering them on the ligand in the crystal structure using 
the default box size setting in Glide. Scaling of van der Waals radii of protein atom's 
partial atomic charge of less than 0.25 in 1.0. Hydrogen bond constraints were not 
applied. The prepared ligands were docked against the target proteins. All docking 
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calculations were performed using the “Extra precision” (XP) mode of Glide program. 
Glide uses a hierarchical series of filter to search for possible locations of the ligand in 
the active site region of the receptor. The initial filters test the spatial fit of the ligand to 
the defined active site and examined the ligand-receptor interactions using a grid-based 
method. Poses that pass these initial screens enter the final stage of the algorithm, 
which involves evaluation and minimization of a grid approximation to the OPLS-AA 
non-bonded ligand-receptor interaction energies. Final scoring is then carried out on the 
energy-minimized poses. The minimized poses are restored using Schrödinger’s 
proprietary Glide score (G score) scoring function. G score is a modified version of 
ChemScore, but includes a steric-clash term and adds buried polar terms devised by 
Schrödinger to penalize electrostatic mismatches.  
G Score = (a x vdW) + (b x Coul) + Lipo + Hbond + Metal + BuryP + RotB + Site 
Where, vdW – van der Waal energy, Coul – Coulomb energy, Lipo – Lipophilic contact 
term, Hbond – Hydrogen bond, Metal – Metal binding term, BuryP – penalty for buried 
polar groups, RotB – penalty for freezing rotatable bonds, Site – polar interaction of the 
active site. 
4.2.1.4. ADMET property Prediction 
 Many drugs often fail to enter the market as a result of poor pharmacokinetic 
profiles. Thus, it has become imperative nowadays to design lead compounds which 
can be easily orally absorbed, easily transported to their desired site of action, not easily 
metabolized into toxic metabolic products before reaching the targeted site of action 
and easily eliminated from the body before accumulating in sufficient amounts that 
may produce adverse side effects. The sum of the above mentioned properties is often 
referred to as ADME (absorption, distribution, metabolism and elimination) properties, 
or better still ADMET, ADME/T or ADMETox (when considerations are given to 
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toxicity issues). The inclusion of pharmacokinetic considerations at earlier stages of 
drug discovery programs using computer-based methods is becoming increasingly 
popular. The rationale behind in silico approaches are the relatively lower cost and the 
time factor involved, when compared to standard experimental approaches for ADMET 
profiling. As an example, it only takes a minute in an in silico model to screen 20,000 
molecules, but takes 20 weeks in the “wet” laboratory to do the same exercise. A set 
of ADMET-related properties (a total of 46 molecular descriptors) were calculated by 
using the QikProp program (Schrödinger) running in normal mode. QikProp generates 
physically relevant descriptors, and uses them to perform ADMET predictions. An 
overall ADME-compliance score – drug-likeness parameter (indicated by #stars), was 
used to assess the pharmacokinetic profiles of the test compounds. The #stars parameter 
indicates the number of property descriptors computed by QikProp that fall outside the 
optimum range of values for 95% of known drugs.(QikProp, Schrodinger). The 
methods implemented were developed by Jorgensen and Duffy  and among the 
calculated descriptors are: the logarithm of predicted binding constant to human serum 
albumin, log KHSA (range for 95% of drugs: -1.5 to 1.2) the logarithm of predicted 
blood/brain barrier partition coefficient, log B/B (range for 95% of drugs: -3.0 to 1.0) 
the predicted apparent Caco-2 cell membrane permeability (BIPcaco − 2) in Boehringer–
Ingelheim scale, in nm s-1 (range for 95% of drugs: < 5 low, > 100 high) the predicted 
apparent Madin-Darby canine kidney (MDCK) cell permeability in nm s-1 (< 25 poor, > 
500 great) calculated from the number of hydrogen bond acceptors (HBA), donors 
(HBD) and the predicted IC50 value for blockage of HERG K+ channels, log HERG 
(concern < −5) the predicted skin permeability, log Kp (−8.0 to −1.0 for 95% of 
drugs) and the number of likely metabolic reactions, #metab (range for 95% of drugs: 
1–8) (Fidele Ntie-Kang, 2013). 
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4.2.2 In-vitro screening  
4.2.2.1. Mammalian cell culture 
 The LNCaP and PC3 cell lines are obtained from NCCS, Pune. LNCaP cells are 
maintained in Roswell Park Memorial Institute (RPMI) medium supplemented with 
10% FBS and penicillin–streptomycin, whereas PC-3 cells were maintained in the 
Dulbecco’s Modified Eagle Medium (DMEM) containing 10% FBS, penicillin–
streptomycin, L-glutamine, pyruvate sodium. Cells were grown at 37°C with 5% CO2. 
PC3 cells are grown in culture flasks with polystyrene surface. The LNCaP cells are 
grown in culture flasks with corning Cell BIND surface. 0.25 % trypsin is used for 
detachment of the cells. (Claudia et al., 2007). 
4.2.2.2. Maintaining and storage of cell lines 
 LNCaP cells show a steady growth rate with a doubling time of 60 hrs whereas 
PC3’s doubling time is 48 hrs. The cells reached confluence in 6 to 7 days and were 
passed to get cells for experiment and also to store liquid nitrogen. Passaging was done 
as follow as. 
 Culture medium was removed from T25 flask by decanting into a clean 
container inside the laminar airflow hood, cells were rinsed with Phosphate Buffer 
Solution (PBS) to remove the traces of serum. 2ml of trypsin was added to the flask 
containing cells and incubate at 37˚C for 2 to 2.5 minutes. As soon as, cells started 
dislodging from the surface, the flask was rinsed with culture medium to arrest 
trypsination. The suspension of cells was collected in a sterile 15ml centrifuge tube 
using serological pipette and the cells were pelleted at 1500rpm for 5 mins. The cell 
pellet was resuspended in PBS and again centrifuged. The resulted pellet is resuspended 
in Culture medium and a part of it was seeded back into a sterile flask. The remaining 
cells were pelleted  and resuspend in cryopreservative medium (10% DMSO in serum) 
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in a cryovial and frozen at -80˚C for short term storage and at liquid nitrogen for long 
time storage. 
4.2.2.3. Drug Preparation 
 Cucurbitacin I was subjected to solubility test with different organic solvents 
and found to be dissolved in DMSO, 50mM concentration was prepared. The desired 
doses such as 0.1, 0.5, 0.10 and 50 mm were prepared from the stock using DMSO. 
4.2.2.4. Anti-proliferative assay  
Approximately 1000 to 3000 cells/well were added in 96 well plate from well 
grown culture, the viability is tested using tryptan blue dye with the help of 
haemocytometer, 95% viability should be confirmed. The anti-proliferative activity is 
measured by adding standard and test compounds (0.1 nM to 500 nM). The 
proliferative activity of the standard and test compound was evaluated without 1nM 
DHT. After 24 hours, fresh medium containing the drug replaces the old medium and 
incubated for another 24 hour. At the end of 48th hr 10µl of  3-[4, 5-dimethyl thiazol-2-
yl] 2, 5- diphenyl tetra-zolium bromide (MTT) is added and the plates were incubated 
for an additional 4 hour. The formazon crystals were dissolved in 100µl of DMSO/well. 
The optical density was measured at 570nm. (Sanchez et al., 2006). By plotting dose 
response curve the IC50 value will be calculated. The cell viability can be calculated 
using the formula,  
Cell viability = (O.D of test cells/O.D of control) Χ 100 
 
4.2.2.5. Dose finalization 
 Based on the IC50 value of test compound of different doses in LNCaP and 
PC3, final dose concentration is fixed for further studies on mechanism of apoptosis.   
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4.2.3. Elucidation of apoptotic mechanism 
4.2.3.1. Gene expression study 
RNA isolation  
Homogenize cell samples in TRIZOL reagent.  Lyse the cells directly in the 
culture dish. Use 1 ml of the TRIZOL reagent per 10 cm2 of glass culture plate surface 
area. After addition of the reagent, the cell lysate was passed several times through a 
pipette to form a homogenous lysate. Isolate cells by centrifugation and then lyse in 
TRI reagent by repeated pipeting. To ensure complete dissociation of nucleoprotein 
complexes, allow samples to stand for 5 minutes at room temperature. Add 0.2 ml of 
chloroform per ml of TRI reagent used. The sample was shaken vigorously for 15 
seconds, and allowed to stand for 2–15 minutes at room temperature. Centrifuged the 
resulting mixture at 12,000 × g for 15 minutes at 2–8 °C. Centrifugation separates the 
mixture into 3 phases: a red organic phase (containing protein), an inter phase 
(containing DNA), and a colorless upper aqueous phase (containing RNA). The 
aqueous phase was transferred to a fresh tube and add 0.5 ml of 2-propanol per ml of 
TRI reagent used in sample preparation. Allow the sample to stand for 5– 10 minutes at 
room temperature. Centrifuged the sample at 12,000 × g for 10 minutes at 2–8 °C. The 
RNA precipitate will form a pellet on the side and bottom of the tube. Remove the 
supernatant and wash the RNA pellet by adding a minimum of 1 ml of 75% ethanol per 
1 ml of TRI reagent used in sample preparation. The sample was vortexed and then 
centrifuged at 7,500 × g for 5 minutes at 2–8 °C. Briefly dry the RNA pellet for 5–10 
minutes by air-drying. The RNA pellet should not be dried completely, as this will 
greatly decrease its solubility. Appropriate volume of DEPC water was added to the 
RNA pellet. To facilitate dissolution, mix by repeated pipeting with a micropipette at 
55–60 °C for 10–15 minutes.  
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Preparation of cDNA from RNA 
 The cDNA was converted from 1µg of the total RNA using high capacity 
cDNA conversion kit. The synthesis of DNA from an RNA template, via reverse 
transcription, produces complementary DNA (cDNA). Reverse transcriptases (RTs) use 
an RNA template and a short primer complementary to the 3' end of the RNA to direct 
the synthesis of the first strand cDNA, which can be used directly as a template for the 
Polymerase Chain Reaction (PCR). This combination of reverse transcription and PCR 
allows the detection of low abundance RNAs in a sample, and production of the 
corresponding cDNA, thereby facilitating the cloning of low copy genes. After initial 
denaturation for 10 min at 95 °C, further denaturation done for 30 sec at 95 °C followed 
by annealing at 60 °C for 45sec and extension at 72 °C for 15sec thirty five 
amplification cycles were performed for PSA, Bax and Bcl2. 
   Table 7: Primers for gene expression 
Gene Primer NCBI 
BAX F: 5’-GGGGACGAACTGGACAGTAA-3’  
R: 5’-CAGTTGAAGTTGCCGTCAGA-3’ 
NM_001291428 
Bcl2 F: 5’- CAGGATAACGGAGGCTGGGATG-3’  
R: 5-GACTTCACTTGTGGCCCAGAT-3’ 
NM_000633.2 
PSA F: 5'-CCGGAAGTGGATCAAGGACA-3',  
R: 5'- GGCCTGGTCATTTCCAAGGT-3', 
NM_001648.2 
  
4.2.3.2. Caspase assay 
 Caspase 3, 8, 9 enzyme activity will be assayed by using a calorimetric caspase 
assay kit. LNCaP cells were treated with 25nM of Cu I and concurrently incubated a 
control culture without induction. Count cells and pellet 1-5 × 106 cells. Resuspend 
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cells in 50 µl of chilled cell lysis buffer and incubate cells on ice for 10 minutes. 
Centrifuge for 1 min in a microcentrifuge (10,000 × g). Transfer supernatant to a fresh 
tube and put on ice for immediate assay or aliquot and stored at -80°C. Assay protein 
concentration. Dilute 50-200 µg protein to 50 µl cell lysis buffer for each assay. Add 50 
µl of 2X reaction buffer that contains 10 mM DTT to each sample. Add 5 µl of 4 mM 
DEVD-pNA (caspase 3), IETD-pNA (caspase 8), LEHD-pNA (caspase 9) substrate and 
incubate at 37°C for 1-2 hour. Read samples at 400 or 405 nm in a microtiter plate 
reader. Fold increase in caspase activity can be determined by comparing these results 
with the level of the un-induced control.      
4.2.3.3. Acridine orange and ethidium bromide staining  
 Incubate 25µl of cell suspension (0.5× 106 to 2.0 × 106 cells/ml) with 1 µl of 
AO/EB solution. Mix gently. Each sample should be mixed just prior to microscopy 
quantification. The sample must be evaluated immediately. Place the plate onto a 
microscopic stage of Fluorescence microscope with fluorescence filter and 10X 
objective. Acridine orange is a vital dye and will stain both live and dead cells. 
Ethidium bromide will stain only cells that have lost membrane integrity. Live cells 
will appear uniformly green. Early apoptotic cells will stain green and contain bright 
green dots in the nuclei as a consequence of chromatin condensation and nuclear 
fragmentation. Late apoptotic cells will also incorporate ethidium bromide and 
therefore stain orange, but, in contrast to necrotic cells, the late apoptotic cells will 
show condensed and often fragmented nuclei. Necrotic cells stain orange, but have a 
nuclear morphology resembling that of viable cells, with no condensed chromatin.   
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     5. RESULTS 
5.1. In-silico screening results 
 Cucurbitacin derivatives were evaluated for their binding affinity with AR, 
ERβ, Bcl2, PI3Kα and AKT proteins. Cucurbitacins had binding affinity with AR, Bcl2 
and AKT and not with PI3Kα and ERβ protein. Among the proteins studied, 
cucurbitacin exhibited better binding affinity with androgen receptors (Table 8). In 
androgen receptor, cucurbitacins had similar and more binding affinity as of 
bicaluatmide (G score -9.177) (Table 8). The standard bicalutamide forms H-Bond 
interactions with amino acids Gln711, Arg752, HOH108 and Asn705 (Table - 9, Fig 4). 
Among the cucurbitacins, cucurbitacin I had number of H-Bond interactions with 
androgen receptors. Cucurbitacin I forms H-Bond interaction with Gln711, Arg752, 
Asn705, HOH108, Met749, HOH109, Val746, Met745 and Trp741 (Table 9, Fig 5). 
 Cucurbitacin G, H, K, L, D and I which had a better binding affinity than 
bicalutamide were further evaluated for their ADME and toxicity properties using 
QikProp 4.0, Schrodinger software. Except for molecular weight, the test compounds 
were within the prescribed range of selected properties (Table 10 & 11). Among the 
cucurbitacins, cucurbitacin I have low molecular weight (514 Dalton). Based on the H-
bond interactions and predicted ADME properties, we have selected cucurbitacin I as a 
lead compound and used that for in-vitro studies. 
5.2. In-Vitro results 
5.2.1. Growth optimization 
LNCaP cells were cultured in RPMI medium supplemented with 10% fetal 
bovine serum at 37˚C with 5% CO2. PC3 cells were cultured in DMEM medium 
supplemented with 10% fetal bovine serum at 37˚C with 5% CO2. The doubling time of 
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LNCaP cells and PC3 cells was observed at 60 hour and 34 hours respectively. The 
fully grown LNCaP cell was in spindle shape and PC3 was in spheroid shape. 
5.2.2. MTT assay result 
 The test and standard compounds were evaluated in LNCaP (AR +) and PC3 
(AR-) cell lines. The test and standard compounds were initially evaluated for their 
cytotoxicity from 1µM to 100µM. Cucurbitacin I exhibits 100% cytotoxic effect in the 
lowest tested dose (0.1µM) on LNCaP and PC3 cell lines. Hence the cucurbitacin I was 
evaluated between 1nM to 100nM in LNCaP and PC3 cell lines. Cucurbitacin I 
inhibited the proliferation of LNCaP cells in a dose dependent manner, whereas in PC3 
the inhibition is less. The IC50 value of Cucurbitacin I in androgen receptor positive cell 
line (LNCaP) was found to be 25 nM whereas in androgen receptor negative cell line 
(PC3) was found to be 791 nM (Table 12) (Fig 6). The Cucurbitacin I was 31.4 times 
selective towards the AR positive cell line than the AR negative cell line (Table 14). 
The IC50 of bicalutamide in LNCaP cell line was found to be 45.5 µM whereas in PC3 
cell line it was 66.6µM (Table 13) (Fig 7). Inhibition in PC3 cell lines by bicalutamide 
was dose independent, whereas in LNCaP it was dose dependent. The bicalutamide was 
1.48 times selective towards the AR positive cell line than the AR negative cell line.  
The results indicate that the cucurbitacin I was more selective towards the LNCaP cell 
line than the bicalutamide. Also, the cucurbitacin I was more cytotoxic in LNCaP cell 
line than bicalutamide. This is because the cucurbitacin I was 1796 times more potent 
than bicalutamide in LNCaP cell line. 
5.2.3. Acridine orange/Ethidium bromide staining result 
Acridine orange/Ethidium bromide staining was done in LNCaP cell line treated 
with 25nM cucurbitacin I and solvent DMSO for 48hr. Cells were counted manually for 
total cells, live cells and apoptotic cells. Cells with greenish color indicate live cells and 
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cells with dark red denote necrotic cells. Late apoptotic cells are in reddish orange color 
with condensed chromatin and early apoptotic cells have green condensed chromatin. 
(Fig: 8a, 8b). LNCaP cells treated with 25 nM of Cucurbitacin I had 49.8 % apoptotic 
cells. (Table: 15). Significant increase in apoptosis of Cucurbitacin I treated cell was 
observed in comparison with solvent control. The report of acridine orange and 
ethidium bromide assay confirms the result of MTT assay. 
5.2.4.Caspase assay 
The Caspase 3, 8, 9 assay was done in LNCaP cell line treated with 25 nMCucurbitacin 
I and solvent DMSO for 48hr. The protein concentration assay was done by Bradford’s 
method. Fold increase in caspase 3, 8, 9 was determined by comparing the absorbance 
of Cucurbitacin I treated cells with the control. Fold increase of caspase 3, 8, 9 
activities in LNCaP cells was found to be 2.3, 2.8 and 2.6 respectively. The caspase 
activity was found to be increased (P<0.001) in Cucurbitacin I treated cells in 
comparison to DMSO treated cells. (Table: 16) 
5.3. Gene expression study 
LNCaP cells were treated with standard bicalutamide, Cucurbitacin I and 
DMSO was taken as solvent control.Bax, Bcl2 and GAPDH gene expression pattern of 
control, bicalutamide and cucurbitacin I treated cells are shown in Fig 9a, 9b, 9c. PSA 
and GAPDH gene expression pattern control, DHT, bicalutamide and cucurbitacin I 
treated cells are shown in Fig. 9d and9e. Cells were treated with 10 NM of DHT, which 
serve as a negative control, for the Prostate Specific Antigen gene expression study.  
5.3.1. PSA Gene expression 
 A significant increase in PSA gene expression was observed in DHT treated 
cells (~2.1 fold) in comparison with control (P<0.001). Cucurbitacin I significantly 
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decreased the expression of PSA gene (~0.56 fold) followed by bicalutamide (~0.73 
fold) (P<0.01) (fig 10).  
5.3.2. Bax-Bcl2 gene expression 
Expression of Bcl2 was low (P<0.01) in Cucurbitacin I (~0.56 fold) treated cells 
in comparison to solvent control and standard drug bicalutamide (~0.87 fold) (fig 11). 
Cells treated with Cucurbitacin I (~1.20 fold) showed upstream Bax expression as like 
standard (~1.29 fold). (Fig.12). Cucurbitacin I inhibited the expression of anti-apoptotic 
protein Bcl2 (~0.56 fold) and stimulated the expression of pro-apoptotic protein Bax 
(~1.20 fold).  The ratio between Bax and Bcl2 of bicalutamide and Cucurbitacin I was 
found to be 1.48 and 2.14 respectively. Significant increase in Bax/Bcl2 ratio was 
observed for Cucurbitacin I in comparison with bicalutamide and solvent control. 
(Table: 17) 
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Table 8: Docking of cucurbitacin derivatives with prostate cancer targets 
S. No Cucurbitacin 
derivatives 
AR 
(PDB Id : 
2OZ7) 
ERβ 
(PDB Id : 
4ZI1 ) 
PI3Kα 
(PDB Id : 
4YKN) 
Bcl2 
(PDB Id : 
2W3L) 
AKT 
(PDB Id: 
2KEL) 
1 Cu A     -3.302 
2 Cu B     -3.274 
3 Cu C -5.733   -4.919 -1.507 
4 Cu D -9.201   -4.026 -3.473 
5 Cu E -7.857    -5.168 
6 Cu F -5.977   -.4.256 -5.043 
7 Cu G -10.886    -8.047 
8 Cu H -11.075    -4.364 
9 Cu I -9.043   -4.011 -3.378 
10 Cu J -8.621   -4.912 -5.027 
11 Cu K -9.634   -4.268 -6.232 
12 Cu L -9.338    -3.646 
13 Cu  O -4.906   -4.555 -6.164 
14 Cu P    -5.390 -4.859 
15 Cu Q    -4.576 -4.260 
16 Cu R     -3.664 
17 Cu S     -2.357 
18 Standard -9.177 -8.628 -9.733 -9.895 -11.107 
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Table 9: Interaction of cucurbitacin derivatives with AR 
S.No Cucurbitacinderivative H bond pi – pi 
bond 
Ionic 
bond 
Hydrophobic 
1 Cu C Asn 705, Ala 877    
2 Cu D Asn 705    
3 Cu E Gln 711, Met 745, 
Asn 705 
   
4 Cu F Leu 704, Asn 705    
5 Cu G Asn 705, Arg 752, 
Gln 711, Leu 873, 
Gln 709 
   
6 Cu H Gln 711, HOH, 
Leu873, Asn 705, 
Ala 877 
   
7 Cu I Gln 711, Arg 752,  
Met 749, Asn 705, 
Trp 741, Met 745, 
Val 746 
  
 
 
 
8 Cu J Glu 709    
9 Cu K Asn 705, Gln 711    
10 Cu L Asn 705    
11 Cu  O Asn 705    
12 Standard Gln 711, Arg 752, 
HOH, Asn 705 
Phe 
764 
  
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Table 10: ADME property prediction 
Drug CNS QPLog 
HERG 
QPPCaCO BB QPMD
CK 
QPLogkhs
a 
Metabolism 
Cu 
G 
-2 -3.671 98.6 -1.8 40.4 0.23 9 
Cu 
H 
-2 -3.671 55.0 -2.5 21.5 0.16 9 
Cu L -2 -3.684 76.6 -1.8 48.2 0.31 9 
Cu 
D 
-2 -3.696 85.00 -1.9 30.7 0.39 8 
Cu 
K 
-2 -3.855 116.1 -1.8 34.4 0.28 7 
Cu I -2 -3.647 80.4 -1.8 32.4 0.42 7 
Bic -2 -3.306 163.6 -1.3 562.3 -0.04 2 
TST -2 -5.806 1125.9 -0.2 487.6 0.50 3 
• CNS - is predicted central nervous system activity on a -2 (inactive) to +2 
(active) scale. 
• QPlogKhsa - is predicted binding to human serum albumin, which should in 
the range of 1.5 to 1.5 
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• QPPCaco - is predicted apparent Caco-2 cell permeability in nm/sec. Caco 2 
cells are a model for the gut-blood barrier,  recommended value is <25 poor, 
>500 great. 
• QPlogBB - is predicted blood/brain partition coefficient, which should be in 
the range of -3.0 to 1.2. 
• QPMDCK - predicted apparent MDCK cell permeability in nm/Sec. It’s a 
good mimic for blood brain barrier, recommended value is <25 poor, >500 
great. 
• QPlog HERG - is predicted IC50 for blockage of HERG K+ channels, which 
should be under -5. 
• Metabolism is number of likely metabolic reactions, the range is 1 to 8. 
 
 
 
Table 11: Lipinski Rule of five 
Drug Mol. Wt<500 
daltons 
Donor HB( <5 
) 
Acceptor HB 
(>10) 
Log P (< 5 
) 
Cu G 534.6 4 11.6 2.5 
Cu H 534.6 4 11.6 2.2 
Cu L 532.6 4 10.6 2.8 
Cu D 516.6 4 9.9 2.7 
Cu K 516.6 4 10.9 2.4 
Cucurbitacin 
I 
514.6 4 9.9 2.7 
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Bicalutamide 430.3 1 7.7 2.9 
Testosterone 288.4 1 3.7 3.3 
 
 
 
 
Table 12: % Inhibition of Cucurbitacin I in LNCaP and PC3 cells 
S.No Cucurbitacin I (nM) % Inhibition 
LNCaP PC3 
1 1 0.15±0.02 0.125±0.00 
2 5 2.15±0.09 0.425±0.17 
3 10 7.04±6.3 0.83±7.4 
4 15 21.44±5.2 4.80±3.9 
5 20 49.37±6.6 11.09±3.4 
6 25 58.84±8.2 16.98±5.1 
7 30 85.21±7.4 22.24±4.6 
8 50 92.58±5.7 39.24±5.7 
9 100 100.10±3.1 45.24±3 
10 500 103±6.6 47.24±3.1 
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Table 13: % inhibition of Bicalutamide in LNCaP and PC3 cells 
S.No Bicalutamide 
(µM) 
% Inhibition 
LNCaP PC3 
1 0.1 0.47±0.1 0.16±0.1 
2 0.5 1.82±1.5 0.22±0.2 
3 1 3.03±2.6 0.30±0.3 
4 5 15.14±2.5 0.66±0.1 
5 10 19.57±2.6 0.68±0.1 
6 50 40.91±3.4 1.30±0.7 
7 100 60.04±6.6 12.24±3.4 
8 500 100.58±4.8 92.65±2.32 
 
 
 
Table 14: IC50 value and selectivity of cucurbitacin I and bicalutamide 
S.No Drug IC50 (nmol/L) Selectivity 
(PC3/LNCaP) PC3 LNCaP 
1 Cucurbitacin 
I 
790.99 ± 107.30 25.18±7.09 31.41 
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2 Bicalutamide 66963.33±2453.38 45239±2586.24 1.48 
 
 
 
 
Table 15: % Apoptosis incucurbitacin I treatedLNCaP cells 
Treatment Total no. of 
cells 
No. of Live 
cells 
No. of Apoptotic 
cells 
% 
apoptosis 
CONTROL 121 117 4 3.30 
Cucurbitacin I 
(25nM) 
129.5 65 64.5 49.80*** 
All the values are expressed in mean ± S.D. One way ANOV followed by Post hoc 
analysis Turkey’s multiple comparison test. *** denotes statistical significance of 
treatment group compared to control group at P<0.001. 
 
Table 16: Caspaseactivity of Cucurbitacin I in LNCaP cells 
S. 
No 
Cucurbitacin I in 
LNCaP 
Control (abs 
405nm) 
Cucurbitacin I treated 
(25nM) (abs 405nm) 
Fold Increase in 
Caspase activity 
1 Caspase 3 0.06±0.00 0.14±0.02 2.33*** 
2 Caspase 8 0.06±0.00 0.17±0.011 2.83*** 
3 Caspase 9 0.06±0.00 0.16±0.010 2.66*** 
All the values are expressed in mean ± S.D. One way ANOVA followed by Post hoc 
analysis Turkey’s multiple comparison test. *** denotes statistical significance of 
treatment group compared to Control group at P<0.001. 
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Table 17: Bax- Bcl2 ratio 
S.No Group Bax mRNA 
expression 
Bcl2 mRNA 
expression 
Bax/Bcl2 
ratio 
1 Control 1 1 1 
2 Bicalutamide 1.29 0.87 1.48*** 
3 Cucurbitacin 
I 
1.20 0.56 2.14*** 
All the values are expressed in mean ± S.D. One way ANOVA followed by Post hoc 
analysis Turkey’s multiple comparison test. *** denotes statistical significance of 
treatment group compared to control group at P<0.001. 
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Interaction of bicalutamide with AR 
 
Interaction of Cucurbitacin I with AR 
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All the values are expressed in mean ± S.D. IC
regression curve. 
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Fig 6: Inhibition of cucurbitacin I  
 
50 value was calculated by non
Page 56 
-linear 
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Fig 7: % Inhibition of bicalutamide 
 
All the values are expressed in mean ± S.D. IC50 value was calculated by non-linear 
regression curve. 
 
 
 
Fig 8a:LNCaP cells treated with solvent DMSO 
 
Fig 8b:LNCaP cells treated with Cucurbitacin I 
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Fig 9: Gene expression 
9a. BAX gene expression in LNCaP cells    
 
   Con     Bic       Cu I  
9b. Bcl2 gene expression in LNCaP cells 
 
   Con           BicCu I 
9c GAPDH gene expression in LNCaP cells 
 
    Con        BicCu I  
9d. PSA gene expression in LNCaP cells 
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Con         DHT       Bic       Cu I 
9e. GAPDH  gene expression in LNCaP cells 
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Fig 10: PSA gene expression 
 
All the values are expressed in mean ± S.D. one way ANOVA followed by Post hoc 
analysis Turkey’s multiple comparison test. ## denotes statistical significance of PSA 
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compared to control at P<0.01. ** denotes statistical significance of treatment group 
compared to DHT group at P<0.01. 
Fig 11: Bax gene expression 
 
All the values are expressed in mean ± S.D. One way ANOVA followed by Post hoc 
analysis Turkey’s multiple comparison test.  
Fig 12: Bcl2 gene expression 
. 
All the values are expressed in mean ± S.D. One way ANOVA followed by Post hoc 
analysis Turkey’s multiple comparison test. *, ** denotes statistical significance of 
treatment group compared to control group at P<0.05 and P<0.01 respectively. 
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6. DISCUSSION 
 The present study shows that cucurbitacins are having specific binding affinity 
for the androgen receptor. This was proved by docking studies where cucurbitacins had 
a better G score for androgen receptor rather than other target of prostate cancer. 
Further examination of cucurbitacins for ADME and toxicity properties, we had 
identified cucurbitacin I was the lead molecule among the cucurbitacins A-U. The 
androgen receptors are nuclear receptor which is having a great binding affinity for 
steroidal hormones particularly Dihydrotestosterone. Cucurbitacins are triterpenoids 
which are the precursor of steroids (David, 1998). This may be the reason for the 
androgen selectivity. Additionally the presence of numerous keto-, hydroxyl and 
acetoxy groups are functioning as H-Bond donor/acceptor. These functional groups had 
formed the essential H-Bond interactions with the androgen receptor. 
 The ligand binding pocket of androgen receptor was made of 12α helix and 2β 
sheets which folds together to form a hydrophobic ligand binding pocket. The ligand-
protein interaction was majorly hydrophobic , however hydrogen bond interaction also 
plays a major role in specificity. Docking studies and crystallographic studies revealed 
that ligands which are able to form H-bond interactions with amino acids Asn705, 
Gln711 and Arg752 andwill have strong affinity towards AR (Karine et al., 2006). 
Cucurbitacin I forms H-bond interaction at Gln711, Arg 752, Met 749, Asn 705, HOH 
108, Trp 741, Met 745, HOH  Val 746. Bicalutamide forms H-bond interaction with 
Gln 711, Arg 752, HOH 108, Asn 705. Recent studies revealed that a full antagonist to 
AR (ligands which function as an antagonist to wild type and mutated ARs) forms H-
bond interactions with Gln711 and Arg752 (Chuangxing et al., 2012). The H-bond 
interaction with Arg 752, Gln 711 was essential for antagonist activity. The 
bicalutamide and cucurbitacin I had formed H-bond interaction with those amino acids. 
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 The cucurbitacin I and bicalutamide were screened for its cytotoxicity effect in 
prostate cancer cell lines LNCaP (AR +ve) and PC3 (AR ˗ve). This method of 
screening in LNCaP and PC3 cells could be used to identify the AR selectivity. 
Expression of dihyrotestosterone stimulated prostate specific antigen was significantly 
reduced by cucurbitacin I, this reduction of PSA level (~0.56 fold) was due to anti-
androgenic effect of Cucurbitacin I. The PSA is the Prostate cancer marker and AR 
response element. The cucurbitacin I was found to be 31.4 times selective towards AR 
positive LNCaP cell line and the standard bicalutamide was 1.48 times selective 
towards AR positive LNCaP cells. The potency of Cucurbitacin I in LNCaP was found 
to be 1796 times than bicalutamide. The tremendous potency of cucurbitacin I in 
LNCaP cells could be due to the synergetic effect of AR antagonism and JAK/STAT 
inhibition (Alghasham., 2013). Cucurbitacin I is a novel compound that could be 
further developed to evaluate its in-vivo efficacy.  
 Apoptosis of the Cucurbitacin I treated cells were confirmed by measuring the 
caspase 3, 8, 9 cleavage activity, Bax/Bcl2 gene expression ratio and Ethidium 
bromide/Acridine orange staining. Growth factor withdrawal and intracellular stress 
can induce apoptosis through the intrinsic cell death pathway, while extrinsic apoptosis 
is initiated through transmembrane death receptors. Initiation and execution of these 
processes are regulated by the BCL-2 and caspase families of proteins. Activation of 
the BCL-2 family members Bax and Bak results in mitochondrial outer membrane 
permeabilization (MOMP) and the release of pro-apoptotic proteins, including 
cytochrome c, from the inter-membrane space into the cytosol (Matthew et al.,2013). 
Cytochrome c can then bind apoptotic protease activating factor 1 (Apaf-1) forming the 
apoptosome and activating caspase-9. Once active, caspase-9 can directly cleave and 
activate caspase-3.  
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 The death receptor-mediated pathway is activated upon ligand binding of cell 
surface death receptors such as tumor necrosis factor-α (TNF-α), initiating ligand-
induced receptor trimerization and the formation of death-inducing signaling complex 
(DISC). Once caspase-8, the initiator caspase, is recruited in zymogen form to the 
DISC, it is autocatalytically processed and released from the complex to the cytosol as 
active tetramer to transactivate a number of downstream executioner caspases including 
the dominant executioner caspase, caspase-3 (Lee et al. 2003). The significant increase 
in Caspase 3, 8 and 9 activity of Cucurbitacin I treated cells indicates that apoptosis 
triggers by both extrinsic and intrinsic pathways. Bcl2 is an anti-apoptotic protein that 
was found to be increased in Prostate cancer. The anti-apoptotic protein Bcl2, has been 
associated with the development of androgen-independent prostate cancer due to its 
high levels of expression in androgen-independent tumors in advanced stages of the 
pathology (Catz et al., 2003). Reduction of Bcl2 level is essential for apoptosis in 
prostate cancer cells. The level of Bcl2 mRNA level was significantly reduced in 
Cucurbitacin I (~0.56 folds) treated LNCaP cells, in comparison with bicalutamide 
(~0.87 fold) and solvent control (~ 1 fold).  
 The balance between pro- and anti-apoptotic members of this family can 
determine the cellular fate. Bax and Bcl-2 are the major members of the Bcl-2 family 
which has potential roles in tumor progression and prognosis of different human 
malignancies. Bax promotes cell death through permeabilization of mitochondrial outer 
membrane in response to different cellular stresses. In contrast, Bcl-2 prevents 
apoptosis by inhibiting the activity of Bax. (Mohan et al., 2012) (Hector et al., 2009). 
The Bax/Bcl-2 ratio can act as a rheostat which determines cell susceptibility to 
apoptosis (Raisova et al., 2001). Lower levels of this ratio may lead to resistance of 
human cancer cells to apoptosis. Thus, the Bax/Bcl-2 ratio can affect tumor progression 
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and aggressiveness. (Hemminki et al., 2010). The Bax/Bcl2 ratio of bicalutamide and 
Cucurbitacin I was found to be 1.48 and 2.14 respectively, significant increase in 
Bax/Bcl2 ratio of Cucurbitacin I treated cells in comparison with bicalutamide and 
solvent control was observed.  
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7. SUMMARY AND CONCLUSION 
 The present study identified that the cucurbitacin I had a better binding affinity 
towards androgen receptor and its H-bond interaction with AR protein was similar as of 
standard bicalutamide. Cucurbitacin I satisfies the ADME and toxicity parameter 
studies. Further evaluation of cytotoxity of cucurbitacin I in prostate cancer cell lines 
LNCaP (AR +ve) and PC3 (AR -ve) reveals that cucurbitacin I is more selective toward 
AR positive cell line LNCaP than PC3 cells. Moreover the cytotoxic potency of 
cucurbitacin I in LNCaP cells is 1796 times greater than standard bicalutamide. 
Reduction of prostate specific antigen in cucurbitacin I treated LNCaP than 
dihydrotestosterone treated LNCaP cells shows the anti-androgenic property of 
cucurbitacin I. Apoptosis was confirmed by ethidium bromide/acridine orange staining. 
Upregulation of caspase 3, 8, 9 in cucurbitacin I treated cells was observed. The 
mechanism behind the cytotoxicity could be the activation of both external and internal 
apoptosis pathways. Increased level of Bax/Bcl2 ratio was noted in Cucurbitacin I 
treated LNCaP cells. The higher levels of this ratio may lead the cancer cells to 
apoptosis. We conclude that Cucurbitacin I is an effective and potent anti-androgen 
agent, which cause apoptosis by the activation of external and internal apoptosis 
pathways and by inhibition of anti-apoptotic protein Bcl2 gene expression. 
Cucurbitacin I is a novel agent for androgen dependent prostate cancer. 
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